Keith Katkin

Mr. Keith A. Katkin is an Independent Director at Emergent BioSolutions, Inc., a Chairman at Eledon Pharmaceuticals, Inc. and an Independent Director at Syndax Pharmaceuticals, Inc. He is on the Board of Directors at Emergent BioSolutions, Inc., Syndax Pharmaceuticals, Inc., Brain Injury Association of America, Inc. and Transposon Therapeutics, Inc. Mr. Katkin was previously employed as a Chief Executive Officer & Director by Urovant Sciences Ltd., a President, Chief Executive Officer & Director by Urovant Sciences, Inc., a Chairman by Otic Pharma Ltd., an Independent Director by Rigel Pharmaceuticals, Inc., an Independent Class III Director by Carbylan Therapeutics, Inc., a President, Chief Executive Officer & Director by Avanir Pharmaceuticals, Inc., and a Vice President-Commercial Development by Peninsula Pharmaceuticals, Inc. He also served on the board at CoverMyMeds LLC and MC10, Inc. He received his undergraduate degree from Indiana University and an MBA from UCLA Anderson School of Management.